Review of Recent US Value Frameworks—A Health Economics Approach: An ISPOR Special Task Force Report [6]

Value in Health

Volumn 21, Issue 2, 2018, Pages 155-160

  Willke, Richard J ^a   Neumann, Peter J ^b   Garrison, Louis P ^c   Ramsey, Scott D ^c  

^a International Society for Pharmacoeconomics and Outcomes Research   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

guiding principles; health technology assessment; methodological issues; value frameworks

Indexed keywords

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH EQUITY; HEALTH INSURANCE; HUMAN; MEDICAL SOCIETY; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; UNITED STATES; VALUE ASSESSMENT; ADVISORY COMMITTEE; ECONOMICS; HEALTH CARE DELIVERY; HEALTH CARE POLICY; OUTCOME ASSESSMENT; PHARMACOECONOMICS; PROCEDURES;

ADVISORY COMMITTEES; COST-BENEFIT ANALYSIS; DECISION MAKING; DELIVERY OF HEALTH CARE; ECONOMICS, PHARMACEUTICAL; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; INSURANCE, HEALTH; OUTCOME ASSESSMENT (HEALTH CARE); SOCIETIES, MEDICAL; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES;

EID: 85042284783     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2017.12.011     Document Type: Article

References (49)

1. Neumann, P.J., Cohen, J.T., Measuring the value of prescription drugs. N Engl J Med 373 (2015), 2295–2297.
2. Westrich, K., Current Landscape Assessment: Value Assessment Frameworks. 2016, National Pharmaceutical Council, Washington, DC.
3. Mandelblatt, J.S., Ramsey, S.D., Lieu, T.A., Phelps, C.E., Evaluating frameworks that provide value measures for health care interventions. Value Health 20 (2017), 185–192.
4. Bentley, T.G.K., Cohen, J.T., Elkin, E.B., et al. Validity and reliability of value assessment frameworks for new cancer drugs. Value Health 20 (2017), 200–205.
5. Cohen, J.T., Anderson, J.E., Neumann, P.J., Three sets of case studies suggest logic and consistency challenges with value frameworks. Value Health 20 (2017), 193–199.
6. Institute for Clinical and Economic Review. Value assessment project, a framework to guide payer assessment of the value of medical services, 2015 Available from: http://www.icer-review.org/impact-and-outcomes/value-assessment-project/. [Accessed December 4, 2016].
7. Anderson, J.L., Heidenreich, P.A., Barnett, P.G., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on performance measures and task force on practice guidelines. J Am Coll Cardiol 63 (2014), 2304–2322.
8. Schnipper, L.E., Davidson, N.E., Wollins, D.S., et al. American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33 (2015), 2563–2577.
9. Schnipper, L.E., Davidson, H.E., Wollins, D.S., et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol 34 (2016), 2925–2934.
10. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines) with NCCN Evidence Blocks™. Available from: www.nccn.org/evidenceblocks/. [Accessed December 4, 2016].
11. Memorial Sloan Kettering Cancer Center. DrugAbacus FAQs. Available from: www.drugabacus.org/faqs. [Accessed December 4, 2016].
12. Neumann, P.J., Willke, R.J., Garrison, L.P., A health economics approach to US value assessment frameworks—introduction: an ISPOR Special Task Force report [1]. Value Health 21 (2018), 119–123.
13. Garrison, L.P., Neumann, P.J., Willke, R.J., et al. A health economics approach to US value assessment frameworks—summary and recommendations of the ISPOR Special Task Force report [7]. Value Health 21 (2018), 161–165.
14. Avalere Health/FasterCures. Patient-Perspective Value Framework (PPVF). DRAFT Methodology. 2016, Avalere Health/FasterCures, Washington, DC.
15. Perfetto, E.M., Oehrlein, E.M., Boutin, M., et al. Value to whom? The patient voice in the value discussion. Value Health 20 (2017), 286–291.
16. Gold, M.R., Siegel, J.E., Russell, L.B., Weinstein, M.C., (eds.) Cost-Effectiveness in Health and Medicine, 1996, Oxford University Press, New York, NY.
17. Neumann, P.J., Sanders, G.D., Russell, L.B., et al. Cost-Effectiveness in Health and Medicine. 2017, Oxford University Press, New York, NY.
18. International Society for Pharmacoeconomics and Outcomes Research. Pharmacoeconomic guidelines around the world. Available from: https://www.ispor.org/PEguidelines/index.asp. [Accessed November 17, 2017].
19. Cherny, N.I., Sullivan, R., Dafni, U., et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 26 (2015), 1547–1573.
20. Malone, D.C., Berg, N.S., Claxton, K., et al. International Society for Pharmacoeconomics and Outcomes Research comments on the American Society of Clinical Oncology value framework. J Clin Oncol 34 (2016), 2936–2937.
21. Chandra, A., Shafrin, J., Dhawan, R., Utility of cancer value frameworks for patients, payers, and physicians. JAMA 315 (2016), 2069–2070.
22. Weiner, I.B., Handbook of Psychology, Assessment Psychology. 2003, John Wiley & Sons, Hoboken, NJ.
23. Biotechnology Innovation Organization. BIO principle on the value of biopharmaceuticals. Available from: https://www.bio.org/sites/default/files/files/BIO_PRINCIPLES_ON_THE_VALUE_OF_BIOPHARMACEUTICALS.pdf. [Accessed May 1, 2017].
24. Deloitte-AdvaMed. A Framework for Comprehensive Assessment of Medical Technologies: Defining Value in the New Health Care Ecosystem. 2017, Deloitte-AdvaMed, Washington, DC.
25. National Health Council. Patient-centered value model rubric released. Available from: http://www.nationalhealthcouncil.org/patient-centered-value-model-rubric-released. [Accessed November 17, 2017].
26. National Pharmaceutical Council. Guiding practices for patient-centered value assessment. Available from: http://www.npcnow.org/guidingpractices. [Accessed May 1, 2017].
27. PhRMA. Principles for value assessment frameworks. Available from: http://www.phrma.org/codes-and-guidelines/principles-for-value-assessment-frameworks. [Accessed November 17, 2017].
28. Sorenson, C., Lavezzari, G., Daniel, G., et al. Advancing value assessment in the United States: a multistakeholder perspective. Value Health 20 (2017), 299–307.
29. Institute for Clinical and Economic Review. Overview of the ICER value framework and update for 2017–2019, 2017 June 22. Available from: https://icer-review.org/wp-content/uploads/2017/06/ICER-value-assessment-framework-update-FINAL-062217.pdf. [Accessed November 17, 2017].
30. Institute for Clinical and Economic Review. Proposed adaptation of the ICER value framework for the assessment of treatments for ultra-rare conditions, 2017 July. Available from: https://icer-review.org/wp-content/uploads/2017/05/ICER_Proposed_VAF_Adaptations_Orphan_Drugs_072517.pdf. [Accessed November 17, 2017].
31. Lakdawalla, D.N., Doshi, J.A., Garrison, L.P., Phelps, C.E., Basu, A., Danzon, P.M., Defining elements of value in health care—a health economics approach: an ISPOR Special Task Force report [3]. Value Health 21 (2018), 131–139.
32. Phelps, C.E., Lakdawalla, D.N., Basu, A., Drummond, M.F., Towse, A., Danzon, P.M., Approaches to aggregation and decision making—a health economics approach: an ISPOR Special Task Force report [5]. Value Health 21 (2018), 146–154.
33. Cookson, R., Mirelman, A.J., Griffin, S., et al. Using cost-effectiveness analysis to address health equity concerns. Value Health 20 (2017), 206–212.
34. Verguet, S., Kim, J.J., Jamison, D.T., Extended cost-effectiveness analysis for health policy assessment: a tutorial. Pharmacoeconomics 34 (2016), 913–923.
35. Allen, J.D., Stewart, M.D., Roberts, S.A., Sigal, E.V., The value of addressing patient preferences. Value Health 20 (2017), 283–285.
36. Armstrong, M.J., Mullins, C.D., Value assessment at the point of care: incorporating patient values throughout care delivery and a draft taxonomy of patient values. Value Health 20 (2017), 292–295.
37. Danzon, P.M., Drummond, M.F., Towse, A., Pauly, M.V., Objectives, budgets, thresholds, and opportunity costs—a health economics approach: an ISPOR Special Task Force report [4]. Value Health 21 (2018), 140–145.
38. Neumann, P.J., Cohen, J.T., Weinstein, M.C., Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 371 (2014), 796–797.
39. Woods, B., Revill, P., Sculpher, M., Claxton, K., Country-level cost effectiveness thresholds: initial estimates and the need for further research. 2015, Center for Health Economics Research Paper 109, University of York, York.
40. McCabe, C.K., Claxton, K., Culyer, A.J., The NICE cost-effectiveness threshold: what it is and what it means. Pharmacoeconomics 26 (2016), 733–744.
41. Sculpher, M.J., Claxton, K., Pearson, S.D., Developing a value framework: the need to reflect the opportunity costs of funding decisions. Value Health 20 (2017), 234–239.
42. Barnsley, P., Towse, A., Schaffer, S.K., Sussex, J., Critique of CHE Research Paper 81: Methods for the estimation of the NICE cost effectiveness threshold. 2013, OHE Occasional Paper 13/01, Office of Health Economics, London.
43. Raftery, J.P., NICE's cost-effectiveness range: Should it be lowered?. Pharmacoeconomics 32 (2014), 613–615.
44. Lakdawalla, D., Neumann, P., Budget criteria and drug value assessments: A case of apples and oranges?. September 22 Health Affairs Blog, 2016 September 22.
45. Ciarametaro, M., Abedi, S., Sohn, A., et al. Concerns around budget impact thresholds: not all drugs are the same. Value Health 20 (2017), 230–233.
46. Pettitt, D., Raza, S., Naughton, B., et al. The limitations of QALY: a literature review. J Stem Cell Res Ther, 6, 2016, 334.
47. Bala, M.V., Zarkin, G.A., Are QALYs an appropriate measure for valuing morbidity in acute diseases?. Health Econ 9 (2000), 177–180.
48. Duru, G., Auray, J.P., Beresniak, A., et al. Limitations of the methods used for calculating quality-adjusted life-year values. Pharmacoeconomics 20 (2002), 463–473.
49. McGregor, M., Caro, J.J., QALYs: Are they helpful to decision makers?. Pharmacoeconomics 24 (2006), 947–952.